{"id":"levo-folinic-acid","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"}]},"_chembl":{"chemblId":"CHEMBL3247771","moleculeType":"Small molecule","molecularWeight":"362.52"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by replenishing the body's stores of folate, which is necessary for the production of DNA and RNA. This helps to mitigate the damage caused by methotrexate, a chemotherapy agent that interferes with DNA synthesis.","oneSentence":"Levo-folinic acid is a form of folinic acid used to help counteract the toxic effects of methotrexate.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:18:48.118Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Counteracting the toxic effects of methotrexate"}]},"trialDetails":[{"nctId":"NCT06662786","phase":"PHASE3","title":"A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-10-18","conditions":"Colorectal Neoplasms","enrollment":1000},{"nctId":"NCT05379595","phase":"PHASE1, PHASE2","title":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2022-07-29","conditions":"Advanced or Metastatic Colorectal Cancer","enrollment":225},{"nctId":"NCT07472868","phase":"PHASE3","title":"Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"J. W. A. Burger","startDate":"2026-03-03","conditions":"Locally Advanced Rectal Carcinoma","enrollment":394},{"nctId":"NCT07391618","phase":"PHASE2","title":"Clinical Study on the First-line Treatment of Advanced Colorectal Cancer With Simultaneous Infusion of Levozolinate for Injection and 5-FU","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-05-15","conditions":"Advanced Colorectal Cancer","enrollment":583},{"nctId":"NCT07309952","phase":"PHASE2","title":"Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Yang Hong","startDate":"2025-12-31","conditions":"Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer","enrollment":28},{"nctId":"NCT05959356","phase":"PHASE2","title":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2023-11-09","conditions":"Metastatic Colorectal Cancer","enrollment":198},{"nctId":"NCT05052099","phase":"PHASE1, PHASE2","title":"Phase Ib/II Single-arm Study of mFOLFOX6, Bevacizumab and Atezolizumab in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2021-10-22","conditions":"Biliary Tract Cancer","enrollment":20},{"nctId":"NCT05678257","phase":"PHASE2","title":"A Study of NUC-3373 in Combination With Other Agents in Patients With Colorectal Cancer","status":"TERMINATED","sponsor":"NuCana plc","startDate":"2023-04-18","conditions":"Colorectal Cancer, Colorectal Neoplasms, Colorectal Adenocarcinoma","enrollment":180},{"nctId":"NCT07155629","phase":"PHASE3","title":"Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Helsinki University Central Hospital","startDate":"2025-09-01","conditions":"Pancreatic Cancer Resectable","enrollment":381},{"nctId":"NCT07124884","phase":"PHASE2","title":"5-fluorouracil Plus Panitumumab (Anti-EGFR) and Sotorasib (KRAS G12C Inhibitor) in First-line Treatment of Patients Non-eligible for a Doublet/Triplet Chemotherapy With Advanced Unresectab","status":"NOT_YET_RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2025-08-31","conditions":"Colorectal Carcinoma, KRAS G12C Mutation, Unresectable Colorectal Cancer","enrollment":300},{"nctId":"NCT06793917","phase":"PHASE3","title":"Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-06-07","conditions":"Gastric Cancer","enrollment":269},{"nctId":"NCT05714553","phase":"PHASE1, PHASE2","title":"NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours","status":"TERMINATED","sponsor":"NuCana plc","startDate":"2023-03-08","conditions":"Advanced Cancer, Advanced Solid Tumor, Neoplasm Malignant","enrollment":19},{"nctId":"NCT07070713","phase":"PHASE2","title":"Efficacy and Safety of FOLFOX+Cetuximab vs. FOLFOXIRI+Bevacizumab Both With QL1706 in First-Line Treatment of Left-Sided mCRC","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2025-07-30","conditions":"Metastatic Colorectal Cancer With Left-sided Primary Tumor, Immunotherapy","enrollment":44},{"nctId":"NCT04554836","phase":"PHASE2","title":"MoLiMoR - A Study With FOLFIRI-based First-line Therapy With or Without Intermittent Cetuximab","status":"COMPLETED","sponsor":"TheraOp","startDate":"2020-12-29","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum","enrollment":6},{"nctId":"NCT06988852","phase":"PHASE2","title":"FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2023-05-01","conditions":"Colorectal Liver Metastasis (CRLM)","enrollment":300},{"nctId":"NCT02839915","phase":"PHASE2","title":"Leucovorin for the Treatment of Language Impairment in Children With Autism Spectrum Disorder","status":"ACTIVE_NOT_RECRUITING","sponsor":"Southwest Autism Research & Resource Center","startDate":"2020-08-13","conditions":"Autism Spectrum Disorder","enrollment":56},{"nctId":"NCT03597581","phase":"PHASE1","title":"A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Inspirna, Inc.","startDate":"2018-06-05","conditions":"Gastrointestinal Cancer, Gastrointestinal Neoplasms, Colorectal Cancer","enrollment":89},{"nctId":"NCT05319639","phase":"PHASE1, PHASE2","title":"Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab","status":"RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-02-16","conditions":"Gastric Cancer Stage IV","enrollment":51},{"nctId":"NCT02162563","phase":"PHASE3","title":"Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases","status":"COMPLETED","sponsor":"Dutch Colorectal Cancer Group","startDate":"2014-07","conditions":"Colorectal Cancer, Liver Metastases","enrollment":530},{"nctId":"NCT02578368","phase":"PHASE3","title":"Chemotherapy Alone vs. Chemotherapy + Surgical Resection in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction","status":"COMPLETED","sponsor":"Krankenhaus Nordwest","startDate":"2016-02","conditions":"Gastric Cancer","enrollment":183},{"nctId":"NCT03635021","phase":"PHASE3","title":"Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)","startDate":"2018-10-15","conditions":"Colorectal Cancer","enrollment":419},{"nctId":"NCT06509126","phase":"PHASE3","title":"Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"National Cancer Institute, Naples","startDate":"2024-06-12","conditions":"Colorectal Cancer Stage IV","enrollment":500},{"nctId":"NCT03694522","phase":"PHASE2","title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Five Prime Therapeutics, Inc.","startDate":"2018-09-14","conditions":"Gastric Cancer","enrollment":155},{"nctId":"NCT03343301","phase":"PHASE1","title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Five Prime Therapeutics, Inc.","startDate":"2017-11-30","conditions":"Gastrointestinal Cancer, Gastrointestinal Cancer Metastatic, Gastric Cancer","enrollment":12},{"nctId":"NCT06226857","phase":"PHASE3","title":"Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"City Clinical Oncology Hospital No 1","startDate":"2024-01-17","conditions":"Colorectal Neoplasms, Chemotherapy Effect, Molecular Sequence Variation","enrollment":355},{"nctId":"NCT06197438","phase":"PHASE2","title":"Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2024-01-01","conditions":"Gastric Cancer","enrollment":36},{"nctId":"NCT04310176","phase":"PHASE2","title":"Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"National Cancer Institute, Naples","startDate":"2019-05-24","conditions":"Ras-mutated Metastatic Colorectal Cancer","enrollment":200},{"nctId":"NCT04169347","phase":"PHASE2","title":"FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer","status":"UNKNOWN","sponsor":"Criterium, Inc.","startDate":"2019-12-02","conditions":"Colorectal Cancer Metastatic","enrollment":27},{"nctId":"NCT01718873","phase":"PHASE3","title":"Optimization of Bevacizumab Scheduling With Chemotherapy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"National Cancer Institute, Naples","startDate":"2012-05","conditions":"Colorectal Cancer","enrollment":230},{"nctId":"NCT01327612","phase":"PHASE2","title":"Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-03-03","conditions":"Advanced Solid Tumors, Carcinoid, Colorectal Cancer","enrollment":12},{"nctId":"NCT03516903","phase":"PHASE2, PHASE3","title":"Effect of Methotrexate Carried by a Lipid Nanoemulsion on Left Ventricular Remodeling After STEMI","status":"TERMINATED","sponsor":"University of Sao Paulo","startDate":"2018-04-17","conditions":"Myocardial Infarction, Anterior Wall, Myocardial Remodeling, Ventricular","enrollment":35},{"nctId":"NCT03688230","phase":"PHASE2","title":"Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.","status":"WITHDRAWN","sponsor":"SFJ Pharmaceuticals X, LTD.","startDate":"2019-04","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT03671252","phase":"PHASE3","title":"Prospectively Randomized Control Clinical Trial of FOLFOXIRI Preoperative Chemotherapy Alone on Rectal Cancer in Local Advance Comparing to Oral Capecitabine Combined With Long-term Radiation","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2018-11-16","conditions":"Rectal Cancer","enrollment":776},{"nctId":"NCT02195180","phase":"PHASE2","title":"Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma","status":"COMPLETED","sponsor":"ERYtech Pharma","startDate":"2014-07","conditions":"Pancreatic Adenocarcinoma Metastatic","enrollment":141},{"nctId":"NCT00457691","phase":"PHASE3","title":"Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-06","conditions":"Metastatic Colorectal Cancer","enrollment":768},{"nctId":"NCT00865709","phase":"PHASE2","title":"Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03","conditions":"Metastatic Colorectal Cancer","enrollment":198},{"nctId":"NCT01225744","phase":"PHASE2","title":"Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy","status":"COMPLETED","sponsor":"The Christie NHS Foundation Trust","startDate":"2009-04","conditions":"Metastatic Colorectal Cancer","enrollment":47},{"nctId":"NCT01533740","phase":"","title":"Circulating Regulatory Lymphocytes and Outcome of Metastatic Colorectal Cancer Patients","status":"COMPLETED","sponsor":"University of Rome Tor Vergata","startDate":"2012-03","conditions":"Metastatic Colorectal Cancer","enrollment":31},{"nctId":"NCT00609622","phase":"PHASE2","title":"Randomized Study Of Sunitinib Plus FOLFOX Versus Bevacizumab Plus FOLFOX In Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2008-04","conditions":"Colorectal Neoplasms","enrollment":191},{"nctId":"NCT00214682","phase":"PHASE2","title":"Beyond Ageing Project: A Study for the Prevention of Depression","status":"COMPLETED","sponsor":"Australian National University","startDate":"2005-10","conditions":"Depression, Depressive Disorder","enrollment":909}],"_emaApprovals":[],"_faersSignals":[{"count":5,"reaction":"NAUSEA"},{"count":5,"reaction":"PARAESTHESIA"},{"count":3,"reaction":"ASTHENIA"},{"count":3,"reaction":"BACK PAIN"},{"count":3,"reaction":"DIARRHOEA"},{"count":3,"reaction":"HYPERTRANSAMINASAEMIA"},{"count":3,"reaction":"NEUTROPENIA"},{"count":3,"reaction":"PYREXIA"},{"count":3,"reaction":"THROMBOCYTOPENIA"},{"count":2,"reaction":"CHOLANGITIS"}],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lederfolin"],"phase":"phase_3","status":"active","brandName":"levo-folinic acid","genericName":"levo-folinic acid","companyName":"National Cancer Institute, Naples","companyId":"national-cancer-institute-naples","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Levo-folinic acid is a form of folinic acid used to help counteract the toxic effects of methotrexate. Used for Counteracting the toxic effects of methotrexate.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}